TME PHARMA N.V. |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.2725 EUR | -0.18% |
|
-4.22% | +18.48% |
| Apr. 03 | TME Pharma: Fast Track designation in glioblastoma | CF |
| Apr. 02 | TME Pharma N.V. Receives US FDA Fast Track Designation for Lead Asset NOX-A12 in Brain Cancer | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
TME Pharma N.V. is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. The company specializes in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Its unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma N.V.'s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. Its clinical programs in glioblastoma and pancreatic cancer have delivered very promising results and further development is planned.
Calendar
2024-04-23
- Q4 2023 Earnings Release (Projected)
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +18.48% | 8.25M | |
| -0.10% | 42.07B | |
| +48.83% | 42.16B | |
| +4.43% | 39.77B | |
| -11.36% | 26.68B | |
| +5.67% | 24.68B | |
| -22.84% | 18.68B | |
| -0.20% | 12.11B | |
| +26.30% | 11.99B | |
| +6.91% | 11.06B |
- Stock Market
- Equities
- ALTME Stock
- News TME Pharma N.V.
- NOXXON Pharma N : to Expand Ongoing Early-Stage Brain Cancer Study; Shares Down 5%
